Search Within

Paul K Paik

Formats
  1. Meeting Abstract (168)
  2. Journal Article (83)
  3. Review (4)
  4. Book Section (1)
Groups
  1. Department of Medicine (256)
  2. Solid Tumor Oncology Division (256)
  3. Thoracic Oncology (256)
  4. GSK Faculty (77)
  5. Department of Pathology and Laboratory Medicine (74)
  6. Human Oncology and Pathogenesis Program (55)

More Groups

People
  1. Mark Kris (55)
  2. Marc Ladanyi (47)
  3. Gregory Riely (42)
  4. Natasha Rekhtman (41)
  5. Charles Rudin (40)
  6. Jamie Chaft (33)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (32)
  4. 2022 (39)
  5. 2021 (34)
  6. 2020 (18)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (49)
  3. Annals of Oncology (34)
  4. Clinical Cancer Research (12)
  5. International Journal of Radiation Oncology, Biology, Physics (11)
  6. Clinical Lung Cancer (6)

More Publications

Publishers
  1. Elsevier Inc. (81)
  2. American Society of Clinical Oncology (56)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (22)
  5. Wiley Blackwell (12)
  6. Nature Publishing Group (11)

More Publishers

Results (256)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers
    Meeting Abstract

    Offin, M.; Xu, C.; Jain, H.; Makhnin, A.; Hayes, S. A.; Plodkowski, A. J.; Halpenny, D.; Rudin, C. M.; Kris, M. G.; Drilon, A. E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Ginsberg, M. S.; Plodkowski, A. J.; Kim, R.; Doyle, L. A.; Rudin, C. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • MET inhibitor resistance in patients with MET exon 14-altered lung cancers
    Meeting Abstract

    Guo, R.; Offin, M.; Brannon, A. R.; Chow, A.; Delasos, L.; Somwar, R.; Wilkins, O.; Scott, K.; Tian, Y.; Cecchi, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tepotinib in NSCLC patients with METex14 mutations: Interim results from the phase II VISION study
    Meeting Abstract

    Sakai, H.; Veillon, R.; Cortot, A. B.; Felip, E.; Mazieres, J.; Morise, M.; Sakamoto, T.; Tokito, T.; Atagi, S.; Kato, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Meeting Abstract

    Paik, P.; Cortot, A.; Felip, E.; Sakai, H.; Mazieres, J.; Horn, L.; Griesinger, F.; Bruns, R.; Scheele, J.; Straub, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
    Journal Article

    Morgensztern, D.; Karaseva, N.; Felip, E.; Delgado, I.; Burdaeva, O.; DoĢmine, M.; Lara, P.; Paik, P. K.; Lassen, U.; Orlov, S.; more...
    Lung Cancer (2019)

    Fulltext@MSK | Save
  • A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers
    Journal Article

    Sabari, J. K.; Offin, M.; Stephens, D.; Ni, A.; Lee, A.; Pavlakis, N.; Clarke, S.; Diakos, C. I.; Datta, S.; Tandon, N.; more...
    JNCI: Journal of the National Cancer Institute (2019)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers
    Meeting Abstract

    Paik, P. K.; Srikakulum, A.; Ahn, L. S. H.; Plodkowski, A. J.; Ng, K. K.; McFarland, D.; Fiore, J. J.; Iqbal, A.; Eng, J.; Rudin, C. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228
    Meeting Abstract

    Paik, P. K.; Qeriqi, B.; Ahn, L. S. H.; Ginsberg, M. S.; Tandon, N.; McFarland, D.; Doyle, L. A.; de Stanchina, E.; Rudin, C. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial
    Meeting Abstract

    Felip, E.; Horn, L.; Patel, J. D.; Sakai, H.; Scheele, J.; Bruns, R.; Paik, P. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save